Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 1 de 1
Filter
Add more filters

Database
Language
Journal subject
Affiliation country
Publication year range
1.
Ann Nucl Med ; 2024 Jul 26.
Article in English | MEDLINE | ID: mdl-39060833

ABSTRACT

OBJECTIVE: When patients administered 177Lu-DOTATATE are released or discharged from rooms where radiopharmaceuticals are used, the time required for release or discharge varies across patients. This study investigated whether the amount of radioactivity accumulated on 111In-somatostatine receptor scintigraphy (111In-SRS) performed prior to treatment can predict the 1 cm dose-equivalent rate at a distance of 1 m from the patient on the day after 177Lu-DOTATATE administration. METHODS: Whole-body planar 111In-SRS images were acquired for 21 patients. Pixel values within whole-body and abdominal (35 × 25 cm) regions of interest (ROIs) were converted to radioactivity dose (MBq). The 1 cm dose-equivalent rate (µSv/h) at a distance of 1 m from the patient 18.3 ± 0.5 h after administration of 177Lu-DOTATATE was measured using an ionization survey meter. RESULTS: The following relationships were observed between the radioactivity on 111In-SRS and the 1 cm dose-equivalent rate on the day after administration of 177Lu-DOTATATE: whole-body ROI: y = 0.16x + 5.01 (r = 0.56, p = 0.009), abdominal ROI: y = 0.27x + 5.13 (r = 0.63, p = 0.002). The regression equations indicate that patients cannot be released or discharged from the radiopharmaceutical room the day after 177Lu-DOTATATE administration if the whole-body and abdominal ROI doses are greater than 81 and 48 MBq, respectively, on 111In-SRS. CONCLUSIONS: The amount of radioactivity accumulated on 111In-SRS may be a predictor of release criteria for patients receiving 177Lu-DOTATATE.

SELECTION OF CITATIONS
SEARCH DETAIL